InvestSMART

LTR Pharma Ltd (ASX:LTP)

ALERT: Price-sensitive ASX Announcement for LTP
Current share price for LTP : $0.495 -0.015 (-2.94%)+
Release
20 Jul 2026 8:55AM
Price at Release
$0.510
Full Release
download
Summary
LTR Pharma Ltd has formalized a definitive commercial agreement with Strive Specialties Inc, a leading U.S. Section 503A compounding pharmacy. This agreement, which completes a key part of LTR's U.S. commercialization strategy, sets the framework for the manufacturing, compounding, fulfilment, and distribution of ROXUS® in the United States. It complements LTR Pharma’s existing telehealth agreement with Shed. The agreement enables LTR to utilize Strive Pharmacy’s multi-state platform for nationwide prescription fulfilment and shipping, focusing now on preparing for the ROXUS commercial launch.
Key Points
  • LTR Pharma has executed a definitive commercial agreement with Strive Specialties Inc, a leading U.S. Section 503A compounding pharmacy.
  • The agreement converts a previously announced binding Term Sheet into a comprehensive long-form commercial agreement.
  • This agreement establishes the framework for manufacturing, compounding, fulfilment, and national distribution of ROXUS® in the United States.
  • The partnership with Strive Pharmacy is a key pillar of LTR Pharma’s U.S. commercialization strategy, complementing the Shed telehealth agreement.
  • Strive Pharmacy operates a multi-state platform supporting nationwide prescription fulfilment and shipping.
  • LTR Pharma's focus is now on technology transfer, inventory planning, and operational implementation ahead of the commercial launch of ROXUS.
  • Executive Chairman Lee Rodne highlights the completion of a major component of LTR's U.S. commercialization strategy.
  • Strive Pharmacy President Michael Walker expresses support for the U.S. launch of ROXUS.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.